Mind + Muscle

technical minds + legal muscle


dig deep

Federal Circuit Says Biosimilar Applicants Can Decline Patent Dance

  • 07.23.15
  • Paul A. Calvo, Ph.D
  • Managing IP

Director Paul A. Calvo, Ph.D. discusses the aftermath of Amgen Inc. v. Sandoz Inc. with Managing Intellectual Property, addressing potential consequences the opinion holds for biosimilar applicants and reference product sponsors.

Calvo told Managing IP, "This opens the door for Sandoz to start marketing, and it also lays out at least the initial framework for what requirements people who have already filed are going to need to put forth and which ones they are not going to have to as long as this decision holds."

Related People

Related Services

Related Industries

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.